Tri Locum Partners portfolio
Concentrated managerInvestment firmPortfolio as of Jun 30, 2026 (Q2 2026) · filed with the SEC on Aug 14, 2026 · data updated on Nov 5, 2026 · Q2 2026 13F (filing) ↗ · all its 13F filings ↗
A 13F shows the portfolio at quarter-end and is filed up to 45 days later: these are not real-time positions and they may have changed.
Tri Locum Partners reported a $813M portfolio of 19 positions to the SEC as of the end of Q2 2026. Its largest positions are JNJ, VRTX, LLY. During the quarter it opened Enliven Therapeutics and Revolution Medicines and exited Thermo Fisher Scientific and Nuvalent.
Sections with a free account
What changed this quarter
21 positions with a change (4 new, 9 added to, 6 trimmed, 2 sold). 12 are listed here: those of 0.5 points of the portfolio or more (up to 12).
- Thermo Fisher Scientific−8.0 ppof portfolioSold out9.1% → —
- Enliven Therapeutics+5.4 ppof portfolioNew— → 5.4%
- Intuitive Surgical−69%fewer sharesReduced9.9% → 2.3%
- Axsome Therapeutics+253%more sharesIncreased1.5% → 6.6%
- Vertex Pharmaceuticals+56%more sharesIncreased8.1% → 12.3%
- Nuvalent−3.9 ppof portfolioSold out4.4% → —
- Revolution Medicines+3.5 ppof portfolioNew— → 3.5%
- Madrigal Pharmaceuticals−34%fewer sharesReduced7.6% → 4.5%
- Eli Lilly+24%more sharesIncreased8.0% → 11.3%
- Cytokinetics+2.0 ppof portfolioNew— → 2.0%
- Jazz Pharmaceuticals+40%more sharesIncreased4.2% → 6.6%
- United Therapeutics−33%fewer sharesReduced5.9% → 3.1%
The figure on the right: for positions added to or trimmed, the change in the number of shares (%); for new and sold ones, the points of the portfolio moved (pp). Below, the portfolio weight before → after. Traded weight: what it bought or sold, excluding price effects.
Top holdings
- Johnson & JohnsonJNJ13.3%
- Vertex PharmaceuticalsVRTX12.3%
- Eli LillyLLY11.3%
- Ascendis Pharma A/SASND8.5%
- DexcomDXCM6.8%
- Axsome TherapeuticsAXSM6.6%
- Jazz PharmaceuticalsJAZZ6.6%
- Enliven TherapeuticsELVN5.4%
- ArgenxARGX4.7%
- Madrigal PharmaceuticalsMDGL4.5%
- Revolution MedicinesRVMD3.5%
- United TherapeuticsUTHR3.1%
- TEVA Pharmaceutical IndustriesTEVA3.1%
- Tarsus PharmaceuticalsTARS2.5%
- Intuitive SurgicalISRG2.3%
“Since”: first quarter of the current run, unbroken until today. In the details, prices are the quarter-end prices of the quarters in which it added shares, per the 13F. The manager may have bought at any price within each quarter; the SEC only publishes the value at quarter end.
Portfolio by sector
- ● Health Care 100%
How its portfolio changed (8 quarters)
Q2 2026: 19
Q2 2026: 80%
Q2 2026: 25.7%
Traded turnover: the weight it bought plus the weight it sold in the quarter, divided by two, excluding price moves. The plain “turnover” in the header does include that effect. With a free account: the full history and sectors over time.
Stakes above 5% (13D/13G)
Companies where this filer reported holding 5% or more of the shares. It is the figure from its latest filing on each one; history since December 2024.
How we classify it
Investment firm, per its Form ADV of Apr 6, 2026 (high confidence).
The data, as reported: TRI LOCUM PARTNERS LP (CRD 309678): 7.B private funds: 1 hedge (gross assets $128M); 5.D assets by client type: pooled vehicles 64%, sovereign funds 36% (of $1.1 bn)
The type comes from a rule applied to that data. If it looks wrong, tell us.
Similar managers by type and size
Same type of filer and a 13F portfolio value between a third and three times this one. It is not a comparison of what they hold.
- Think InvestmentsInvestment firm · $811M
- Schwerin Boyle Capital ManagementInvestment firm · $816M
- Parsifal Capital ManagementInvestment firm · $817M
- Sirios Capital ManagementInvestment firm · $822M
- Newtyn ManagementInvestment firm · $801M
- Quantum Capital ManagementInvestment firm · $798M